Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Manno-epi-cyclophellitols Enable Activity-Based Protein Profiling of Human α-Mannosidases and Discovery of New Golgi Mannosidase II Inhibitors.
Armstrong Z, Kuo CL, Lahav D, Liu B, Johnson R, Beenakker TJM, de Boer C, Wong CS, van Rijssel ER, Debets MF, Florea BI, Hissink C, Boot RG, Geurink PP, Ovaa H, van der Stelt M, van der Marel GM, Codée JDC, Aerts JMFG, Wu L, Overkleeft HS, Davies GJ. Armstrong Z, et al. Among authors: johnson r. J Am Chem Soc. 2020 Jul 29;142(30):13021-13029. doi: 10.1021/jacs.0c03880. Epub 2020 Jul 16. J Am Chem Soc. 2020. PMID: 32605368
Improving paclitaxel delivery: in vitro and in vivo characterization of PEGylated polyphosphoester-based nanocarriers.
Zhang F, Zhang S, Pollack SF, Li R, Gonzalez AM, Fan J, Zou J, Leininger SE, Pavía-Sanders A, Johnson R, Nelson LD, Raymond JE, Elsabahy M, Hughes DM, Lenox MW, Gustafson TP, Wooley KL. Zhang F, et al. Among authors: johnson r. J Am Chem Soc. 2015 Feb 11;137(5):2056-66. doi: 10.1021/ja512616s. Epub 2015 Jan 28. J Am Chem Soc. 2015. PMID: 25629952
Correction to "Improving Paclitaxel Delivery: In Vitro and In Vivo Characterization of PEGylated Polyphosphoester-Based Nanocarriers".
Zhang F, Zhang S, Pollack SF, Li R, Gonzalez AM, Fan J, Zou J, Leininger SE, Pavía-Sanders A, Johnson R, Nelson LD, Raymond JE, Elsabahy M, Hughes DM, Lenox MW, Gustafson TP, Wooley KL. Zhang F, et al. Among authors: johnson r. J Am Chem Soc. 2015 Jun 3;137(21):6972. doi: 10.1021/jacs.5b04944. Epub 2015 May 26. J Am Chem Soc. 2015. PMID: 26008821 No abstract available.
Discovery of CHD1 Antagonists for PTEN-Deficient Prostate Cancer.
Johnson RL, Graboski AL, Li F, Norris-Drouin JL, Walton WG, Arrowsmith CH, Redinbo MR, Frye SV, James LI. Johnson RL, et al. J Med Chem. 2024 Nov 7. doi: 10.1021/acs.jmedchem.4c01172. Online ahead of print. J Med Chem. 2024. PMID: 39508435
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Berg SA, La Rosa S, Zhang T, Pierorazio PM, Albiges L, Beckermann KE, Campbell MT, Carlo MI, Coleman K, George DJ, Geynisman DM, Johnson R, Jonasch E, Maranchie JK, McGregor BA, Shapiro DD, Singer EA, Shuch BM, Stadler WM, Tannir NM, Zakharia Y, Vaishampayan UN, Thall PF, Msaouel P. Berg SA, et al. Among authors: johnson r. Urol Oncol. 2024 Nov 4:S1078-1439(24)00701-4. doi: 10.1016/j.urolonc.2024.10.022. Online ahead of print. Urol Oncol. 2024. PMID: 39500687 Free article. Review.
14,182 results
You have reached the last available page of results. Please see the User Guide for more information.